title: The experience of taking multiple drug therapies for persons with HIV infection: the Canadian perspective.
abstract: Advances in the understanding of HIV pathogenesis, clinical assessment with viral load testing, and the availability of potent combination antiretroviral therapy regimens have led to significant benefits for persons with HIV infection. Currently, the therapeutic strategy to achieve high-level suppression of viral replication involves many pills and doses each day. This regimen could adversely affect the quality of life of these clients. In reviewing the literature, it is evident that little is known about the experience of taking multiple drug therapies from the perspective of the individuals. For example, with the introduction of triple drug therapies has come constraints associated with the regimens, as well as drug interactions and short-term and long-term adverse effects. Little is known about the social and emotional impact related to successfully taking these or other therapies. Less is known regarding this experience from a Canadian perspective. This research study answered the following question: What is the experience of taking multiple drug therapies for persons with HIV infection? A phenomenological inquiry was used. A purposive sample of 19 participants was drawn from a large immunodeficiency clinic in a tertiary hospital. In-depth interviews were followed by a return interview to verify themes from the analysis. The findings revealed the complex process that these regimens demand and the major impact on clients' lives. The essence of the experience described by the participants was "learning to live with this process."
authors.affiliation: School of Nursing, Faculty of Health Sciences, University of Ottawa. fbourbon@uottawa.ca
authors.forename: Frances
authors.initials: F
authors.lastname: Fothergill-Bourbonnais
authors.forename: Susan
authors.initials: S
authors.lastname: Laschinger
authors.forename: Diane
authors.initials: D
authors.lastname: Fillion
authors.forename: Nicole
authors.initials: N
authors.lastname: Denommé
authors.forename: Jennifer
authors.initials: J
authors.lastname: Conway-Vendette
authors.forename: Lynda
authors.initials: L
authors.lastname: O'Reilly
authors.forename: Suzanne
authors.initials: S
authors.lastname: Page
authors.forename: Joanne
authors.initials: J
authors.lastname: Thibert
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D002170:Canada; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D012646:Self Administration / Q000523:psychology*; D019562:Viral Load; D014779:Virus Replication
chemical_list: D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors